CAMBRIDGE, Massachusetts and TORONTO, Ontario, July 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody ...

"We are extremely pleased with the significant progress our team achieved in 2025 and the strong momentum we have carried into 2026," said Neil Warma, Chief Executive Officer of ProMIS Neurosciences. ...

ProMIS Neurosciences Inc. PMN shares skyrocketed Monday after the company presented preclinical data supporting the potential therapeutic advantage of its lead candidate for Alzheimer's disease (AD), ...

ProMIS Neurosciences Inc., a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases, announced progress in its clinical programs and shared insights from its ...

Phase 1b trial in Alzheimer’s disease is over 85% enrolled: Cohorts 1 and 2 are fully enrolled PMN310 continues to demonstrate a favorable safety profile On track to report 6-month interim data in Q2 ...

Proceeds expected to enable completion of ProMIS’ landmark Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line data expected mid-2026; 12-month top-line data ...

ProMIS Neurosciences Inc. (Nasdaq:PMN), a clinical-stage biotechnology firm specializing in treatments for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) ...

The latest price target for ProMIS Neurosciences (NASDAQ:PMN) was reported by HC Wainwright & Co. on December 1, 2025. The analyst firm set a price target for $18.00 expecting PMN to rise to within 12 ...

ProMIS Neurosciences Inc., a clinical-stage biotechnology firm, announced its plan to present preclinical data on novel computationally-derived vaccines targeting neurodegenerative diseases at the ...

PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early ...